Table 2.
Reports on rituximab treatment in C3 glomerulopathy and dense-deposit disease. RTX: rituximab, C3GN: C3 glomerulopathy, DDD: dense-deposit disease, MMF: mycophenolate mofetil, RAS: renin angiotensin system, C3Nef: C3 nephritic factor, TCC: terminal complement complex, CFH: complement factor H, CFI: complement factor I, MCP: membrane cofactor protein, and CR and PR: complete and partial remission (as defined by the authors).
| Authors | Diagnosis | Follow-up | Other therapy | RTX protocol | Laboratory parameters | Outcome |
|---|---|---|---|---|---|---|
| Daina et al. [41] | DDD | 5 months for RTX 48 months for eculizumab |
Steroids Eculizumab RAS blockade |
1 × 375 mg/m2 | C3Nef positive C3 < 10% TCC high Genetics (CFH variants V62 and H402) |
No effect of RTX on renal function or proteinuria PR with eculizumab |
|
| ||||||
| Rousset-Rouvière et al. [42] | DDD | 21 months | Steroids MMF Eculizumab RAS blockade |
2 × 375 mg/m2 | C3 < 0.04 g/L C4 normal C3Nef positive Genetics: normal (CFH, CFI, MCP) Anti-CFH negative |
Acute renal failure after RTX CR with eculizumab |
|
| ||||||
| Giaime et al. [40] | DDD | 30 months | RAS blockade | 4 × 700 mg weekly repeated after 18 months |
Creatinine 235 μmol/L Proteinuria 6 g/day C3 0.12 g/L (low) C4 normal C3Nef positive |
Creatinine 200 µmol/L Proteinuria < 0.5 g/L C3 remained low C3Nef remained positive |
|
| ||||||
| Payette et al. [43] | C3GN | 72 months | Steroids MMF Eculizumab |
4 × 375 mg/m2 | Proteinuria 1–5.3 g/day C3Nef positive CFI mutation (I398L) anti-CFH positive low C3 |
No effect of RTX on proteinuria PR with eculizumab Normal renal function |